Target intelligence / Profile preview

Urokinase plasminogen activator receptor (uPAR)

Target: uPAR
Molecular classification: Receptor

Overview

Urokinase plasminogen activator receptor (uPAR) is a GPI-anchored cell surface receptor that binds urokinase-type plasminogen activator (uPA) and plays a central role in the plasminogen activation system, promoting pericellular proteolysis. It is involved in cell adhesion, migration, tissue remodeling, angiogenesis, inflammation, and wound healing. uPAR is highly expressed in many malignant tumors and cancer-associated stromal cells, making it a therapeutic target. Soluble uPAR (suPAR) serves as a biomarker for systemic inflammation and chronic disease burden.

Other names: MO3Monocyte activation antigen Mo3U-PARUPARPLAUR

Mechanism of action

Suppression of tumor growth, metastatic spread, and drug resistance mechanisms via uPAR inhibition; Senolysis via targeted CAR-T therapy.

Biological functions

Plasminogen activationCell adhesionCell migrationTissue remodelingAngiogenesisInflammationWound healingSignaling cascadesCytoskeletal dynamics

Disease associations

CancerInflammationCOPDAsthmaLiver failureHeart failureCardiovascular diseaseRheumatoid arthritis

Safety considerations

Potential for off-target effects with uPAR-targeted therapies due to its role in normal physiological processes like wound healing and immune function.Risk of triggering unintended immune responses or cytokine release syndrome with CAR-T therapies.

Interacting drugs

Monoclonal antibodies targeting uPAR

7 more in the full profile.

Biomarkers

suPAR (soluble uPAR) as a biomarker for systemic inflammation and chronic disease burdenuPAR expression level as a prognostic marker in cancer

Beyond the preview

Go deeper on Urokinase plasminogen activator receptor (uPAR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Urokinase plasminogen activator receptor (uPAR).

Explore the full profile